Thyroid disease

Global Nuclear Medicine Market Share, Size, Trends, Industry Analysis Report 2021-2028 - ResearchAndMarkets.com

Retrieved on: 
Monday, June 28, 2021
Pharmaceutical, Health, Oncology, Anatomy, Branches of biology, Medicinal radiochemistry, Nuclear medicine, Radiology, Thyroid, Thyroid disease, Nuclear medicine physician, Internal medicine

The "Nuclear Medicine Market Share, Size, Trends, Industry Analysis Report, By Type; By Modality; By Application; By End-Use; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Nuclear Medicine Market Share, Size, Trends, Industry Analysis Report, By Type; By Modality; By Application; By End-Use; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • However, nuclear medicine is increasingly being used in therapeutic procedures for the treatment of cancer and thyroid-related conditions.
  • The different applications of nuclear medicine in the market include thyroid, cardiology, bone metastasis, oncology, neurology, gastroenterology, immunology, and others.
  • Increasing applications in cancer detection and the presence of well-established healthcare infrastructure further increases the demand for Nuclear Medicine in North America.

Gail Devers, Three-Time Olympic Gold Medalist, Partners with the Graves’ Community to FOCUS on Thyroid Eye Disease

Retrieved on: 
Monday, June 28, 2021
General Health, Other Health, Health, Pharmaceutical, Optical, Thyroid disease, Anatomy, Autoimmune diseases, Organ systems, Organs anatomy), Graves' disease, Thyroid, Gail Devers, GD, Autoimmunity, Book:Thyroid, British Thyroid Foundation, Gail Devers, Graves’ Disease, Thyroid Eye Disease, The Graves’ Disease and Thyroid Foundation, Prevent Blindness, Horizon, GAIL DEVERS, GRAVES’ DISEASE, THYROID EYE DISEASE, THE GRAVES’ DISEASE AND THYROID FOUNDATION, PREVENT BLINDNESS, HORIZON

Horizon and Devers are collaborating with The American Autoimmune Related Diseases Association , the Graves Disease and Thyroid Foundation and Prevent Blindness to help people living with Graves disease FOCUS on their eye health.

Key Points: 
  • Horizon and Devers are collaborating with The American Autoimmune Related Diseases Association , the Graves Disease and Thyroid Foundation and Prevent Blindness to help people living with Graves disease FOCUS on their eye health.
  • Gail Devers is a world-renowned track star and three-time Olympic gold medalist who has been living with Graves disease and symptoms of TED for more than 30 years.
  • After a harrowing two-and-a-half-year quest for answers, she was diagnosed with Graves disease in 1990, just two years before winning her first Olympic gold medal.
  • The Graves Disease and Thyroid Foundation (GDATF) is the leading source of help and hope for people with Graves disease and other thyroid related disorders.

Thyroid Cancer Pipeline Insight Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 24, 2021
Pharmaceutical, Health, Oncology, Anatomy, Thyroid disease, Branches of biology, Organs anatomy), Endocrine diseases, Endocrine system, Glands, Thyroid, Pipeline, Drug pipeline

The "Thyroid Cancer - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Thyroid Cancer - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Thyroid cancer - Pipeline Insight, 2021" report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Thyroid cancer pipeline landscape.
  • This segment of the report provides insights about the different Thyroid cancer drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • Thyroid cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Global Thyroid Eye Disease (TED) Clinical Landscape Market Report 2021: Marketed and Pipeline Drugs, Trials, Key Events, Probability Of Success, 10-Year Disease Prevalence Forecast, Deals, Revenue - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 17, 2021
Pharmaceutical, Optical, Health, Clinical trials, Anatomy, Thyroid disease, Autoimmune diseases, Organ systems, Branches of biology, Thyroid, Graves' ophthalmopathy, Graves' disease, Autoimmune disease, Autoimmunity, TED, Hashimoto's thyroiditis

The "Market Spotlight: Thyroid Eye Disease (TED)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Market Spotlight: Thyroid Eye Disease (TED)" report has been added to ResearchAndMarkets.com's offering.
  • Thyroid eye disease (TED), also called Graves' ophthalmopathy or orbitopathy, is an autoimmune disorder that causes inflammation in the orbital and retroocular tissues.
  • The negative impact of TED on the social and psychological well-being of individuals is an established consequence of the disease.
  • Thyroid eye disease (TED) is associated with thyroid disease, and most commonly occurs in Graves' disease, where it is estimated to be present in ~40% of patients.

Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ASCO 2021

Retrieved on: 
Monday, June 7, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Anatomy, Thyroid disease, Organ systems, Cyclopropanes, Orphan drugs, Organs anatomy), Cabozantinib, Quinolines, Exelixis, Thyroid cancer, Ipsen, Thyroid nodule, CABOMETYX, CABOMETYX

Exelixis, Inc. (NASDAQ: EXEL) and Ipsen (Euronext:IPN; ADR:IPSEY) today announced detailed results from the phase 3 COSMIC-311 pivotal trial of cabozantinib (CABOMETYX) in patients with previously treated radioactive iodine-refractory differentiated thyroid cancer (DTC).

Key Points: 
  • Exelixis, Inc. (NASDAQ: EXEL) and Ipsen (Euronext:IPN; ADR:IPSEY) today announced detailed results from the phase 3 COSMIC-311 pivotal trial of cabozantinib (CABOMETYX) in patients with previously treated radioactive iodine-refractory differentiated thyroid cancer (DTC).
  • COSMIC-311 is a global, multicenter, randomized, double-blind, placebo-controlled phase 3 pivotal trial that aimed to enroll approximately 300 patients at 150 sites globally.
  • In 2016, Exelixis granted Ipsen exclusive rights for the commercialization and further clinical development of cabozantinib outside of the United States and Japan.
  • Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer.

Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ASCO 2021

Retrieved on: 
Monday, June 7, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Anatomy, Thyroid disease, Organ systems, Cyclopropanes, Orphan drugs, Organs anatomy), Cabozantinib, Quinolines, Exelixis, Thyroid cancer, Ipsen, Thyroid nodule, CABOMETYX, CABOMETYX

Exelixis, Inc. (NASDAQ: EXEL) and Ipsen (Euronext:IPN; ADR:IPSEY) today announced detailed results from the phase 3 COSMIC-311 pivotal trial of cabozantinib (CABOMETYX) in patients with previously treated radioactive iodine-refractory differentiated thyroid cancer (DTC).

Key Points: 
  • Exelixis, Inc. (NASDAQ: EXEL) and Ipsen (Euronext:IPN; ADR:IPSEY) today announced detailed results from the phase 3 COSMIC-311 pivotal trial of cabozantinib (CABOMETYX) in patients with previously treated radioactive iodine-refractory differentiated thyroid cancer (DTC).
  • COSMIC-311 is a global, multicenter, randomized, double-blind, placebo-controlled phase 3 pivotal trial that aimed to enroll approximately 300 patients at 150 sites globally.
  • In 2016, Exelixis granted Ipsen exclusive rights for the commercialization and further clinical development of cabozantinib outside of the United States and Japan.
  • Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer.

Novo Nordisk receives FDA approval for Wegovy™ to treat adults with obesity based on unprecedented efficacy for a prescription medicine in clinical trials

Retrieved on: 
Friday, June 4, 2021
Anatomy, Branches of biology, Health, Thyroid disease, Endocrine diseases, Aging-associated diseases, Endocrine system, Glands, Thyroid, Weight loss, Medication, Cancer

Expanding safe and clinically effective treatment options for obesity management is good news for people with obesity and the medical community."

Key Points: 
  • Expanding safe and clinically effective treatment options for obesity management is good news for people with obesity and the medical community."
  • It is not known if Wegovy is safe and effective when taken with other prescription, over-the- counter, or herbal weight loss products.
  • In studies with rodents, Wegovy and medicines that work like Wegovy caused thyroid tumors, including thyroid cancer.
  • Do not use Wegovy if:
    you have had a serious allergic reaction to semaglutide or any of the ingredients in Wegovy.

Global Thyroid Cancer Markets, Epidemiology and Patient Flow Analysis Report 2020-2035 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 25, 2021
Pharmaceutical, Health, Oncology, Other Health, Anatomy, Thyroid disease, Organ systems, Glands, Endocrine diseases, Aging-associated diseases, Thyroid cancer, Thyroid, Cancer, Computed tomography of the thyroid, Thyroid nodule

The "Global Thyroid Cancer Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Thyroid Cancer Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Global Thyroid Cancer Epidemiology and Patient Flow Analysis - 2021, provides Thyroid Cancer epidemiology, demographics, and patient flow.
  • The research provides population data to characterize Thyroid Cancer patients, history of the disease at the population level (Thyroid Cancer prevalence, Thyroid Cancer incidence) and at the clinical level (from diagnosis to treated patients).
  • Demographics: Thyroid Cancer patients by age group, gender
    The data from this research will help executives:
    Establish basis for Thyroid Cancer market sizing, assessing market potential, and developing drug forecast models
    Identify Thyroid Cancer patients segments through age groups, gender, and disease sub-types
    Evaluate Thyroid Cancer market opportunities, identify target patient population
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210525005754/en/

Insights on the Thyroid Cancer Diagnostics Global Market to 2028 - Share, Size, Trends and Industry Analysis Report - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 13, 2021
Biotechnology, Health, Oncology, Anatomy, Thyroid disease, Organ systems, Branches of biology, Thyroid cancer, Thyroid, Cancer, Papillary thyroid cancer

b'The "Thyroid Cancer Diagnostics Market Share, Size, Trends, Industry Analysis Report, By Type; By Technique; By End-Use; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com\'s offering.\nThe global thyroid cancer diagnostics market size is expected to reach USD 3.84 billion by 2028 according to a new study.

Key Points: 
  • b'The "Thyroid Cancer Diagnostics Market Share, Size, Trends, Industry Analysis Report, By Type; By Technique; By End-Use; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com\'s offering.\nThe global thyroid cancer diagnostics market size is expected to reach USD 3.84 billion by 2028 according to a new study.
  • The report gives a detailed insight into current market dynamics and provides analysis on future market growth.\nThe high prevalence rate of thyroid cancer in the market, huge unmet medical needs, drug approvals, and research initiatives to deal with early diagnosis are the prominent drivers responsible for the market growth.
  • It is being estimated that each year, around 53,000 people in the U.S. alone expected to diagnose with thyroid cancer.
  • RET-activated mutations are key instigators in many cancer forms, including thyroid cancers.

MEDO receives FDA approval to Revolutionize Thyroid Ultrasound.

Retrieved on: 
Thursday, May 6, 2021
Anatomy, Branches of biology, Thyroid disease, Endocrine system, Glands, Thyroid, Nodule, Medo, Thyroid cancer

This high volume is due to the fact that lumps, or "nodules" on the thyroid gland are common and although usually benign, can be cancerous.

Key Points: 
  • This high volume is due to the fact that lumps, or "nodules" on the thyroid gland are common and although usually benign, can be cancerous.
  • Using artificial intelligence, Medo has revolutionized the process of performing thyroid studies and turned it into a seamless, fast,and objective workflow.\nWith Medo-Thyroid, the user simply obtains quick video \'sweeps\' of each side of the thyroid gland.
  • Jacob Jaremko, a radiologist and co-founder of Medo, explains that "Medo-Thyroid makes thyroid ultrasound a less frustrating test, by presenting thyroid measurements and nodule characteristics in a convenient format.
  • Dornoosh Zonoobi, co-founder and CEO of Medo, notes that: "With this product, Medo provides both clinical and financial value to the stakeholders.